Vertex Plans $375M Notes Offering

Xconomy Boston — 

Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ:VRTX) said today that it plans to offer an estimated $375 million worth of convertible senior subordinated notes due in 2015 in a public offering. The firm has granted its underwriter, BofA Merrill Lynch, the option to purchase up to $25 million in additional notes under the same terms of the offering. Vertex, which has significant operations in San Diego, is planning to file for FDA approval of its experimental hepatitis C drug by the end of the year.